newsfilter
← Latest News
ClinicalTrials.gov·

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants - NCT05501717

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), Maximum Observed Plasma Concentration (Cmax), Time to Maximum Observed Plasma Concentration (Tmax), (and 4 more...)